Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics Statistics
Share Statistics
Adaptimmune Therapeutics has 42.65M shares outstanding. The number of shares has increased by 3.67% in one year.
| Shares Outstanding | 42.65M |
| Shares Change (YoY) | 3.67% |
| Shares Change (QoQ) | 0.07% |
| Owned by Institutions (%) | 59.29% |
| Shares Floating | 37.75M |
| Failed to Deliver (FTD) Shares | 13.09K |
| FTD / Avg. Volume | 0.8% |
Short Selling Information
The latest short interest is 5.35M, so 2.09% of the outstanding shares have been sold short.
| Short Interest | 5.35M |
| Short % of Shares Out | 2.09% |
| Short % of Float | 2.36% |
| Short Ratio (days to cover) | 4.71 |
Valuation Ratios
The PE ratio is -1.4 and the forward PE ratio is -1.24. Adaptimmune Therapeutics's PEG ratio is 0.03.
| PE Ratio | -1.4 |
| Forward PE | -1.24 |
| PS Ratio | 2.65 |
| Forward PS | 0.1 |
| PB Ratio | 4.04 |
| P/FCF Ratio | -1.09 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Adaptimmune Therapeutics has an Enterprise Value (EV) of 40.7M.
| EV / Earnings | -0.36 |
| EV / Sales | 0.68 |
| EV / EBITDA | -0.32 |
| EV / EBIT | -0.29 |
| EV / FCF | -0.28 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.64.
| Current Ratio | 2.85 |
| Quick Ratio | 2.85 |
| Debt / Equity | 0.64 |
| Total Debt / Capitalization | 38.97 |
| Cash Flow / Debt | -5.58 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.88% and return on capital (ROIC) is -215.72%.
| Return on Equity (ROE) | -2.88% |
| Return on Assets (ROA) | -0.4% |
| Return on Capital (ROIC) | -215.72% |
| Revenue Per Employee | $134,256.12 |
| Profits Per Employee | $-253,610.24 |
| Employee Count | 449 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.34M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -66.04% in the last 52 weeks. The beta is 2.41, so Adaptimmune Therapeutics's price volatility has been higher than the market average.
| Beta | 2.41 |
| 52-Week Price Change | -66.04% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 38.75 |
| Average Volume (20 Days) | 1.63M |
Income Statement
In the last 12 months, Adaptimmune Therapeutics had revenue of 60.28M and earned -113.87M in profits. Earnings per share was -0.09.
| Revenue | 60.28M |
| Gross Profit | 50.42M |
| Operating Income | -138.04M |
| Net Income | -113.87M |
| EBITDA | -128.2M |
| EBIT | -138.04M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 143.99M in cash and 25.23M in debt, giving a net cash position of 118.76M.
| Cash & Cash Equivalents | 143.99M |
| Total Debt | 25.23M |
| Net Cash | 118.76M |
| Retained Earnings | -1.02B |
| Total Assets | 317.44M |
| Working Capital | 180.76M |
Cash Flow
In the last 12 months, operating cash flow was -140.88M and capital expenditures -4.88M, giving a free cash flow of -145.76M.
| Operating Cash Flow | -140.88M |
| Capital Expenditures | -4.88M |
| Free Cash Flow | -145.76M |
| FCF Per Share | -0.12 |
Margins
Gross margin is 83.65%, with operating and profit margins of -228.99% and -188.9%.
| Gross Margin | 83.65% |
| Operating Margin | -228.99% |
| Pretax Margin | -186.68% |
| Profit Margin | -188.9% |
| EBITDA Margin | -212.67% |
| EBIT Margin | -228.99% |
| FCF Margin | -241.8% |
Dividends & Yields
ADAP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.67% |
| FCF Yield | -635.4% |
Analyst Forecast
The average price target for ADAP is $3.15, which is 483.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.15 |
| Price Target Difference | 483.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -3.71 |
| Piotroski F-Score | 4 |